Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluvoxamine for premenstrual dysphoric disorder: a pilot study

E W Freeman1, K Rickels, S J Sondheimer

  • 1Department of Obstetrics/Gynecology, School of Medicine, University of Pennsylvania, Philadelphia 19104, USA.

The Journal of Clinical Psychiatry
|January 1, 1996
PubMed
Summary

Fluvoxamine shows promise in treating premenstrual dysphoric disorder (PDD). This pilot study found significant symptom improvement in women taking the medication daily for two cycles.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does AMH relate to timing of menopause? Results of an Individual Patient Data meta- analysis.

The Journal of clinical endocrinology and metabolism·2018
Same author

Replication Of Symptom Distress Factors In Anxious Neurotic Outpatients.

Multivariate behavioral research·2016
Same author

Daily salivary cortisol patterns in midlife women with hot flashes.

Clinical endocrinology·2015
Same author

Re: Over-the-counter drugs for the treatment of mood and anxiety disorders--the views of German pharmacists. By J. Hamann, K. Linde, H. D. Schweiger, O. Kusmakow, H. Foerstl, Pharmacopsychiatry 2014; 47: 84-88.

Pharmacopsychiatry·2014
Same author

Hormone variations associated with quantitative fat measures in the menopausal transition.

Climacteric : the journal of the International Menopause Society·2013
Same author

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.

The pharmacogenomics journal·2012

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Serotonergic agents are emerging as effective treatments for premenstrual symptoms.
  • Previous small trials suggest efficacy for premenstrual symptoms.

Purpose of the Study:

  • To gather pilot data on the efficacy of fluvoxamine for premenstrual dysphoric disorder (PDD).

Main Methods:

  • An open-label study evaluated 10 women meeting DSM-IV criteria for PDD.
  • Subjects took daily fluvoxamine for two menstrual cycles, with doses adjusted to 100 mg/day by week 8.
  • Daily symptom reports (DSRs) and Hamilton Rating Scale for Depression scores were primary outcome measures.

Main Results:

  • Mean premenstrual DSR scores significantly improved at 4 and 8 weeks compared to baseline.

Related Experiment Videos

  • Key symptom improvements included irritability, anxiety, feeling out of control, and decreased interest.
  • Sixty percent of subjects achieved at least a 50% reduction in DSR scores; depression scores also decreased significantly.
  • Common side effects like insomnia, fatigue, dry mouth, and nausea were generally mild and transient.

    • Conclusions:

    • Pilot data suggest fluvoxamine is a promising treatment for premenstrual dysphoric disorder (PDD).
    • Further controlled trials over longer durations are necessary to confirm efficacy.